177 related articles for article (PubMed ID: 19714866)
1. Protective protein/cathepsin A rescues N-glycosylation defects in neuraminidase-1.
Wang D; Zaitsev S; Taylor G; d'Azzo A; Bonten E
Biochim Biophys Acta; 2009 Apr; 1790(4):275-82. PubMed ID: 19714866
[TBL] [Abstract][Full Text] [Related]
2. Elimination of abnormal sialylglycoproteins in fibroblasts with sialidosis and galactosialidosis by normal gene transfer and enzyme replacement.
Oheda Y; Kotani M; Murata M; Sakuraba H; Kadota Y; Tatano Y; Kuwahara J; Itoh K
Glycobiology; 2006 Apr; 16(4):271-80. PubMed ID: 16361247
[TBL] [Abstract][Full Text] [Related]
3. In Cellulo Crystallization of Human Neuraminidase 1 and Biological Roles of
Tsukimoto J; Takeuchi Y; Horii Y; Iniwa T; Fukushi Y; Nishioka SI; Itoh K
ACS Appl Bio Mater; 2022 Jan; 5(1):205-213. PubMed ID: 35014832
[TBL] [Abstract][Full Text] [Related]
4. Chaperone-mediated gene therapy with recombinant AAV-PPCA in a new mouse model of type I sialidosis.
Bonten EJ; Yogalingam G; Hu H; Gomero E; van de Vlekkert D; d'Azzo A
Biochim Biophys Acta; 2013 Oct; 1832(10):1784-92. PubMed ID: 23770387
[TBL] [Abstract][Full Text] [Related]
5. Heterodimerization of the sialidase NEU1 with the chaperone protective protein/cathepsin A prevents its premature oligomerization.
Bonten EJ; Campos Y; Zaitsev V; Nourse A; Waddell B; Lewis W; Taylor G; d'Azzo A
J Biol Chem; 2009 Oct; 284(41):28430-28441. PubMed ID: 19666471
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy corrects the neurological deficits of mice with sialidosis.
Hwu WL; Chang K; Liu YH; Wang HC; Lee NC; Chien YH
Gene Ther; 2024 May; 31(5-6):263-272. PubMed ID: 38321198
[TBL] [Abstract][Full Text] [Related]
7. [Orientation of three lysosomal enzymes in the mouse inner ear and hearing loss in enzyme gene deficiency].
Guo YK; Xie DH; Yang XM
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Feb; 31(1):79-84. PubMed ID: 16562682
[TBL] [Abstract][Full Text] [Related]
8. Short-term, high dose enzyme replacement therapy in sialidosis mice.
Wang D; Bonten EJ; Yogalingam G; Mann L; d'Azzo A
Mol Genet Metab; 2005 Jul; 85(3):181-9. PubMed ID: 15979029
[TBL] [Abstract][Full Text] [Related]
9. Intermittent enzyme replacement therapy with recombinant human β-galactosidase prevents neuraminidase 1 deficiency.
Luu AR; Wong C; Agrawal V; Wise N; Handyside B; Lo MJ; Pacheco G; Felix JB; Giaramita A; d'Azzo A; Vincelette J; Bullens S; Bunting S; Christianson TM; Hague CM; LeBowitz JH; Yogalingam G
J Biol Chem; 2020 Sep; 295(39):13556-13569. PubMed ID: 32727849
[TBL] [Abstract][Full Text] [Related]
10. The NEU1-selective sialidase inhibitor, C9-butyl-amide-DANA, blocks sialidase activity and NEU1-mediated bioactivities in human lung in vitro and murine lung in vivo.
Hyun SW; Liu A; Liu Z; Cross AS; Verceles AC; Magesh S; Kommagalla Y; Kona C; Ando H; Luzina IG; Atamas SP; Piepenbrink KH; Sundberg EJ; Guang W; Ishida H; Lillehoj EP; Goldblum SE
Glycobiology; 2016 Aug; 26(8):834-49. PubMed ID: 27226251
[TBL] [Abstract][Full Text] [Related]
11. In silico identification of new putative pathogenic variants in the NEU1 sialidase gene affecting enzyme function and subcellular localization.
Bonardi D; Ravasio V; Borsani G; d'Azzo A; Bresciani R; Monti E; Giacopuzzi E
PLoS One; 2014; 9(8):e104229. PubMed ID: 25153125
[TBL] [Abstract][Full Text] [Related]
12. Lysosomal sialidase NEU1, its intracellular properties, deficiency, and use as a therapeutic agent.
Itoh K; Tsukimoto J
Glycoconj J; 2023 Dec; 40(6):611-619. PubMed ID: 38147151
[TBL] [Abstract][Full Text] [Related]
13. Elastogenesis in cultured dermal fibroblasts from patients with lysosomal beta-galactosidase, protective protein/cathepsin A and neuraminidase-1 deficiencies.
Tatano Y; Takeuchi N; Kuwahara J; Sakuraba H; Takahashi T; Takada G; Itoh K
J Med Invest; 2006 Feb; 53(1-2):103-12. PubMed ID: 16538002
[TBL] [Abstract][Full Text] [Related]
14. Splice donor site mutation in the lysosomal neuraminidase gene causing exon skipping and complete loss of enzyme activity in a sialidosis patient.
Penzel R; Uhl J; Kopitz J; Beck M; Otto HF; Cantz M
FEBS Lett; 2001 Jul; 501(2-3):135-8. PubMed ID: 11470272
[TBL] [Abstract][Full Text] [Related]
15. Lysosomal multienzyme complex: pros and cons of working together.
Bonten EJ; Annunziata I; d'Azzo A
Cell Mol Life Sci; 2014 Jun; 71(11):2017-32. PubMed ID: 24337808
[TBL] [Abstract][Full Text] [Related]
16. Systemic and neurologic abnormalities distinguish the lysosomal disorders sialidosis and galactosialidosis in mice.
de Geest N; Bonten E; Mann L; de Sousa-Hitzler J; Hahn C; d'Azzo A
Hum Mol Genet; 2002 Jun; 11(12):1455-64. PubMed ID: 12023988
[TBL] [Abstract][Full Text] [Related]
17. Type I sialidosis, a normosomatic lysosomal disease, in the differential diagnosis of late-onset ataxia and myoclonus: An overview.
Caciotti A; Melani F; Tonin R; Cellai L; Catarzi S; Procopio E; Chilleri C; Mavridou I; Michelakakis H; Fioravanti A; d'Azzo A; Guerrini R; Morrone A
Mol Genet Metab; 2020 Feb; 129(2):47-58. PubMed ID: 31711734
[TBL] [Abstract][Full Text] [Related]
18. Enzymatic activity of lysosomal carboxypeptidase (cathepsin) A is required for proper elastic fiber formation and inactivation of endothelin-1.
Seyrantepe V; Hinek A; Peng J; Fedjaev M; Ernest S; Kadota Y; Canuel M; Itoh K; Morales CR; Lavoie J; Tremblay J; Pshezhetsky AV
Circulation; 2008 Apr; 117(15):1973-81. PubMed ID: 18391110
[TBL] [Abstract][Full Text] [Related]
19. New mutations in the PPBG gene lead to loss of PPCA protein which affects the level of the beta-galactosidase/neuraminidase complex and the EBP-receptor.
Malvagia S; Morrone A; Caciotti A; Bardelli T; d'Azzo A; Ancora G; Zammarchi E; Donati MA
Mol Genet Metab; 2004 May; 82(1):48-55. PubMed ID: 15110321
[TBL] [Abstract][Full Text] [Related]
20. Clinical and electrophysiological characteristics of a type 1 sialidosis patient with a novel deletion mutation in NEU1 gene.
Fan SP; Lee NC; Lin CH
J Formos Med Assoc; 2020 Jan; 119(1 Pt 3):406-412. PubMed ID: 31371146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
